Market Overview

UPDATE: Stifel Terminates Coverage on Corcept Therapeutics Due to Reallocation of Resources

Share:
Related CORT
Benzinga's Top Initiations
Warrant Exercises Generate $17.2M; Proceeds to Advance Next-Generation Compounds and Support Commercialization of Korlym

In a report published Monday, Stifel analyst Annabel Samimy terminated coverage on Corcept Therapeutics (NASDAQ: CORT).

In the report, Stifel noted, “Due to a reallocation of resources, we are discontinuing coverage of Corcept Therapeutics. Our last rating was Hold. Our last net loss estimates were ($0.53) for FY 2014, ($0.38) for 2015, breakeven for FY2016, $0.40 for FY2017, and $1.12 for FY 2018. However, these estimates should not be used as an indicator for the company going forward.”

Corcept Therapeutics closed on Friday at $4.08.

Latest Ratings for CORT

DateFirmActionFromTo
Apr 2015FBR CapitalInitiates Coverage onOutperform
Mar 2015Piper JaffrayUpgradesNeutralOverweight
Apr 2014Brinson PatrickInitiates Coverage onMarket Outperform

View More Analyst Ratings for CORT
View the Latest Analyst Ratings

Posted-In: Annabel Samimy StifelAnalyst Color Termination Analyst Ratings

 

Related Articles (CORT)

Around the Web, We're Loving...